Tong Ren Tang Technologies Co. Ltd. (TGRNF)
USD 0.69
(0.0%)
USD 0.69
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.84 Billion CNY | 9.87% |
| 2022 | 2.59 Billion CNY | 13.12% |
| 2021 | 2.29 Billion CNY | 10.81% |
| 2020 | 2.06 Billion CNY | 0.64% |
| 2019 | 2.05 Billion CNY | -15.38% |
| 2018 | 2.42 Billion CNY | -3.86% |
| 2017 | 2.52 Billion CNY | 6.74% |
| 2016 | 2.36 Billion CNY | 18.82% |
| 2015 | 1.99 Billion CNY | 23.28% |
| 2014 | 1.61 Billion CNY | 12.07% |
| 2013 | 1.44 Billion CNY | 15.8% |
| 2012 | 1.24 Billion CNY | 32.76% |
| 2011 | 937.49 Million CNY | 23.05% |
| 2010 | 761.85 Million CNY | 24.53% |
| 2009 | 611.77 Million CNY | 13.03% |
| 2008 | 541.23 Million CNY | 9.16% |
| 2007 | 495.8 Million CNY | 8.37% |
| 2006 | 457.52 Million CNY | -20.4% |
| 2005 | 574.79 Million CNY | 7.97% |
| 2004 | 532.35 Million CNY | 12.76% |
| 2003 | 472.09 Million CNY | 32.54% |
| 2002 | 356.2 Million CNY | 38.96% |
| 2001 | 256.32 Million CNY | 54.9% |
| 2000 | 165.48 Million CNY | 17.73% |
| 1999 | 140.56 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 213.25 Million USD | 0.0% |
| 2023 FY | 2.84 Billion CNY | 9.87% |
| 2023 Q2 | 226.07 Million USD | 0.0% |
| 2023 Q4 | 177.12 Million USD | 0.0% |
| 2022 Q4 | 186.53 Million USD | 0.0% |
| 2022 Q2 | 198.93 Million USD | 0.0% |
| 2022 FY | 2.59 Billion CNY | 13.12% |
| 2021 Q2 | 192.94 Million USD | 0.0% |
| 2021 FY | 2.29 Billion CNY | 10.81% |
| 2021 Q4 | 161.8 Million USD | 0.0% |
| 2020 FY | 2.06 Billion CNY | 0.64% |
| 2020 Q4 | 154.31 Million USD | 0.0% |
| 2020 Q2 | 145.49 Million USD | 0.0% |
| 2019 Q2 | 190.09 Million USD | 0.0% |
| 2019 FY | 2.05 Billion CNY | -15.38% |
| 2019 Q4 | 109.97 Million USD | 0.0% |
| 2018 FY | 2.42 Billion CNY | -3.86% |
| 2017 FY | 2.52 Billion CNY | 6.74% |
| 2016 FY | 2.36 Billion CNY | 18.82% |
| 2015 FY | 1.99 Billion CNY | 23.28% |
| 2014 FY | 1.61 Billion CNY | 12.07% |
| 2013 FY | 1.44 Billion CNY | 15.8% |
| 2012 FY | 1.24 Billion CNY | 32.76% |
| 2011 FY | 937.49 Million CNY | 23.05% |
| 2010 FY | 761.85 Million CNY | 24.53% |
| 2009 FY | 611.77 Million CNY | 13.03% |
| 2008 FY | 541.23 Million CNY | 9.16% |
| 2007 FY | 495.8 Million CNY | 8.37% |
| 2006 FY | 457.52 Million CNY | -20.4% |
| 2005 FY | 574.79 Million CNY | 7.97% |
| 2004 FY | 532.35 Million CNY | 12.76% |
| 2003 FY | 472.09 Million CNY | 32.54% |
| 2002 FY | 356.2 Million CNY | 38.96% |
| 2001 FY | 256.32 Million CNY | 54.9% |
| 2000 FY | 165.48 Million CNY | 17.73% |
| 1999 FY | 140.56 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 91.792% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 91.701% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 90.552% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -25240.901% |
| Novartis AG | 34.18 Billion USD | 91.671% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -283.007% |